GH Research PLC

NASDAQ:GHRS

Biotechnology

Healthcare
$18.25 -0.18%

-$0.04 today

Market cap
$1.25B
Beta
1.31
P/E (TTM)
-23.8
EPS (TTM)
-$0.91
52W Low $11.32High $25.94

Volume 0.46M

Average 0.23M

GHRS EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

GH Research PLCNASDAQ: GHRS

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA remains negative

Q1 FY2026 EBITDA was -$18.79M, compared with -$10.73M a year earlier. Trailing-twelve-month EBITDA was -$55.86M.

Context

  • EBITDA grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the -23.0% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$18.79M-34.6% QoQ
Last fiscal yearDec 2025
-$47.46M-23.0% YoY
LTMMar 2026
-$55.86M-33.8% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-75.2%+100.0%+175.2 pp
1 year-23.0%+100.0%+123.0 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(47.46M) USD
Year-over-year change
-23.0%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How GHRS compares with its peers on the latest reported figures

  • GHRS's LTM Mar 2026 EBITDA of -$55.86M is the 2nd highest of the 9 companies compared; the peer median is -$208.27M.
  • Its year-over-year change of -33.8% is the 5th highest of 8, against a peer median of -28.2%.
GHRS Competitors Peer median
EBITDA for GHRS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LBRXLB Pharmaceuticals Inc Common StockLTM Mar 2026-$39.05M ———
GHRSGH Research PLCLTM Mar 2026-$55.86M -33.8%——
ANROAlto Neuroscience, Inc.LTM Mar 2026-$71.29M -16.9%——
RAPPRapport Therapeutics, Inc. Common StockLTM Mar 2026-$118.15M -28.2%—590.7%
MPLTMapLight Therapeutics, Inc.LTM Mar 2026-$198.91M -147.8%——
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026-$217.64M +15.4%——
DFTXDefinium Therapeutics, Inc.LTM Sep 2026-$323.53M -99.1%——
NERVMinerva Neurosciences, Inc.LTM Jun 2026-$394.35M -3608.6%——
BHVNBiohaven Ltd.LTM Jun 2026-$574.94M +24.1%——
SPTXSeaport Therapeutics, Inc. Common Stock—— ———
Peer median (excluding GHRS) -$208.27M-28.2%—590.7%

Competitors are the stored peer set for GHRS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue0000335K
Gross Profit0000(335K)
Gross Margin—————
Research & Development8.55M20.48M29.82M35.02M38.73M
Selling, General & Admin6.54M10.06M11.12M15M21.61M
Operating Expenses15.1M30.55M41.22M50.31M60.34M
Depreciation & Amortization19K47K315K315K335K
EBITDA(9.17M)(22.41M)(35.21M)(38.6M)(47.46M)
EBITDA Margin—————
Operating Income(15.1M)(30.55M)(41.22M)(50.31M)(60.68M)
Operating Margin—————
Interest Income9858K1.89M2.63M2.63M
Interest Expense9K—723K717K463K
Other Income / Expenses5.9M8.1M5.64M11.35M12.42M
Income Before Tax(9.2M)(22.46M)(35.59M)(38.96M)(48.26M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(9.2M)(22.46M)(35.59M)(38.96M)(48.26M)
Net Margin—————
EPS (Basic)(0.18)(0.14)(0.68)(0.75)(0.79)
EPS (Diluted)(0.18)(0.14)(0.68)(0.75)(0.79)
Weighted Avg Shares52.02M52.02M52.02M52.03M61.04M
Weighted Avg Shares (Diluted)52.02M52.02M52.02M52.03M61.04M

GH Research PLC

NASDAQ:GHRS

Intrinsic Alpha fair value

Locked

Current Price

$18.25

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.